MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2D ^Low T cells.

Autor: Toyoda H; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.; Department of Orthopedic Surgery, Showa University School of Medicine, Tokyo, 142-8555, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan., Hosonuma M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan., Murayama M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.; Department of Otorhinolaryngology, Showa University School of Medicine, Tokyo, 142-8555, Japan., Narikawa Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.; Department of Otorhinolaryngology, Showa University School of Medicine, Tokyo, 142-8555, Japan., Isobe J; Department of Hospital Pharmaceutics, Showa University School of Pharmacy, Tokyo, 142-8555, Japan., Baba Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Tajima K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan., Funayama E; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.; Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, 142-8555, Japan., Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan., Maruyama Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan., Sasaki A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Kobayashi S; Department of Otorhinolaryngology, Showa University School of Medicine, Tokyo, 142-8555, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Hida N; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Division of Clinical Research and Development, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, 142-8555, Japan., Sambe T; Division of Clinical Research and Development, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, 142-8555, Japan., Nobe K; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.; Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, 142-8555, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, 157-8577, Japan., Kobayashi H; Department of Otorhinolaryngology, Showa University School of Medicine, Tokyo, 142-8555, Japan., Tsuji M; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, 157-8577, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan., Kudo Y; Department of Orthopedic Surgery, Showa University School of Medicine, Tokyo, 142-8555, Japan., Kiuchi Y; Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan., Yoshimura K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan. kyoshim1@med.showa-u.ac.jp.; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan. kyoshim1@med.showa-u.ac.jp.

Publikováno v: Scientific reports [Sci Rep] 2024 Oct 08; Vol. 14 (1), pp. 23401. Date of Electronic Publication: 2024 Oct 08.

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.

Autor: Murayama M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Hosonuma M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan., Kobayashi S; Department of Otorhinolaryngology, Fujigaoka Hospital, Yokohama, Japan., Sasaki A; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Baba Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan., Narikawa Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Toyoda H; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Orthopaedic Surgery, School of Medicine, Showa University, Tokyo, Japan., Isobe J; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan., Funayama E; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan., Tajima K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan., Sasaki A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Maruyama Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Yamazaki Y; Pharmacological Research Center, Showa University, Tokyo, Japan.; Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan., Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan., Hamada K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tsurui T; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Sambe T; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan., Tsuji M; Pharmacological Research Center, Showa University, Tokyo, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Shimane T; Head and Neck Oncology Center, Showa University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kobayashi H; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Kiuchi Y; Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Yoshimura K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11, Kitakarasuyama, Setagaya-ku, Tokyo, 157-8577, Japan. kyoshim1@med.showa-u.ac.jp.; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.

Publikováno v: Scientific reports [Sci Rep] 2024 May 17; Vol. 14 (1), pp. 11325. Date of Electronic Publication: 2024 May 17.

Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.

Autor: Otsuka K; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Isobe J; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan., Asai Y; Department of Systems Bioinformatics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.; AI Systems Medicine Research and Training Center, Graduate School of Medicine, Yamaguchi University and Yamaguchi University Hospital, Yamaguchi, Japan., Nakano T; Department of Systems Bioinformatics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan., Hattori K; Research Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.; Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Ariyoshi T; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Yamashita T; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Motegi K; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Saito A; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Kohmoto M; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Hosonuma M; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Baba Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Murayama M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Narikawa Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan., Toyoda H; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.; Department of Orthopedic Surgery, School of Medicine, Showa University, Tokyo, Japan., Funayama E; Division of Pharmacology, Department of Pharmacology, School of Pharmacy, Showa University, Tokyo, Japan., Tajima K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Gastroenterological Surgery, Tokai University School of Medicine, Tokyo, Japan., Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Sambe T; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan., Tsuji M; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Kiuchi Y; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Goto S; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Murakami M; Showa University Hospital Esophageal Cancer Center, Esophageal Surgery, Tokyo, Japan., Kim YG; Research Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.; Pharmacological Research Center, Showa University, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jan 27; Vol. 73 (2), pp. 23. Date of Electronic Publication: 2024 Jan 27.

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.

Autor: Ohkuma R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Miura S; Department of Pathology, Showa University School of Medicine, Tokyo, Japan., Muto S; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Toyomasu Y; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Fujimoto Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Ieguchi K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Onishi N; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Shimizu T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Takayanagi D; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Goshima T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Hamada K; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Shimokawa M; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Iriguchi N; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Mura E; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Takenoshita S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Numajiri K; Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan., Okabe N; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Tsuji M; Pharmacological Research Center, Showa University, Tokyo, Japan., Kiuchi Y; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Yajima T; Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan., Ishida H; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Suzuki H; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Yamochi T; Department of Pathology, Showa University School of Medicine, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Wada S; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Sep 18; Vol. 14, pp. 1260492. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).

Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary.

Autor: Suzuki R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Hamada K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Homma M; Department of Pathology, Showa University School of Medicine, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Iriguchi N; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Wada S; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Yamochi T; Department of Pathology, Showa University School of Medicine, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Jul 10; Vol. 13, pp. 1231986. Date of Electronic Publication: 2023 Jul 10 (Print Publication: 2023).